ERBB2 and breast carcinoma: Some challenges remain to be addressed in utilizing immune response as a predictor in HER2-positive/HR-positive breast cancer: several (but not all [23]) neoadjuvant trials in HER2-positive EBC have shown a strong predictive impact of immune markers (CD8 expression and/or TILs) on pCR [24,25,26].